INDUCED RESPONSES on RAT TRACHEAL, BRONCHIAL and LUNG STRIP in Vitro PREPARATIONS

Total Page:16

File Type:pdf, Size:1020Kb

INDUCED RESPONSES on RAT TRACHEAL, BRONCHIAL and LUNG STRIP in Vitro PREPARATIONS Br. J. Pharmac. (1978), 64, 71-74. A COMPARISON OF DRUG- INDUCED RESPONSES ON RAT TRACHEAL, BRONCHIAL AND LUNG STRIP in vitro PREPARATIONS J.W. BURNS' & J.E. DOE2 Pharmacology and Biochemistry Department, Fisons Ltd, R & D Labs, Bakewell Road, Loughborough, Leics 1 A preparation of rat trachea and a new preparation of rat bronchi are described. Both prep- arations are fluid-filled and the intraluminal pressure is monitored. 2 A preparation of rat peripheral airways, the lung strip, is described. The preparation consists of a thin strip of lung parenchyma which is superfused, and contractions monitored isotonically. 3 The rat trachea and bronchi have no intrinsic tone but increases in pressure are elicited in response to methacholine. The preparations relax in response to isoprenaline and aminophylline in the presence of a methacholine-induced contraction. Both preparations respond weakly and show tachyphylaxis to 5-hydroxytryptamine (5-HT). 4 The lung strip contracts with equal magnitude to methacholine and 5-HT. It exhibits intrinsic tone which is inhibited by indomethacin and relaxed by isoprenaline. Introduction Bronchoconstriction and bronchodilatation in small aration, derived from the lung parenchyma, contains animals have been generally examined by the use of mainly small airways and alveoli which contribute to isolated preparations of major airways or whole ani- compliance changes. mals. The major airways used have been the tracheal tube (Farmer & Coleman, 1970) or the spirally cut trachea (Constantine, 1965). The whole animal prep- Methods arations are usually variations of the technique ori- ginally described by Konzett & Rossler (1947) involv- Rat tracheal tube ing artificial respiration. None of these provide much information about the likely effect of agonists in a Male Charles River CR/CD rats (weight range 250 spontaneously breathing animal. to 350 g) were anaesthetized with 60 mg/kg sodium We have examined the effects of various agonists pentobarbitone (Sagatal', May & Baker Ltd.) intra- using preparations derived from three levels of the peritoneally. The trachea was exposed and excised rat respiratory tract. First, we used an isolated tra- from the larynx to just above the bronchial bifurca- cheal tube preparation similar to that described for tion. The trachea was mounted on a prefabricated the guinea-pig by Farmer & Coleman (1970). block similar to that described by Farmer & Coleman Secondly, we have developed an isolated preparation (1970), filled and immersed iIr a physiological solution of the rat major and lobar bronchi. These two large at 37°C. The solution contained the following (g/l): airway preparations represent the areas which con- NaCl 8.0, NaHCO3 1.0, glucose 1.0, NaH2PO4 0.32, tribute most to resistance or 'bronchoconstriction' MgCl2 0.42, KCI 0.2 and CaCl2 0.1. changes. We have also developed an isolated lung Changes in intraluminal pressure were recorded strip preparation, similar to that from cat lung de- with a Statham P23BB pressure transducer and a scribed by Sparrow & Mitchell (1976). This prep- Vitatron flat bed recorder. Drugs were added to the bathing fluid. 1 Present address: Department of Pharmacology, Gist-Bro- cades, n.v., Postbus 1, Wateringseweg 1, Delft, The Nether- lands. Rat bronchial preparation 2 Present address: Inhalation Toxicity Section, Central Toxicology Laboratory, Imperial Chemical Industries Male Charles River CR/CD (250 to 350 g) rats were Limited, Alderley Park, Macclesfield, Cheshire. anaesthetized as above. The thorax was opened and 72 J.W. BURNS & J.E. DOE b a 10c.11 2 co 8 0co 80 0.0 7 ._ 6 co c 60 . co 5 .E0) I aE E 4 E 40 . oo 3 C 2 0 201. 0C 0) co 0 OL. lOng lOng lpg bOpg 10Oug 1mg lOOng lug lOug 100ug 1mg 10mg loomg Dose of methacholine Figure 1 The effect of methacholine on (a) the rat isolated bronchial preparation, and (b) the lung strip: without atropine sulphate (0); in the presence of atropine sulphate 10ng/ml (U) or 100ng/ml (A). Each point represents the mean results from 5 tissues (a) or 6 tissues (b); vertical lines show s.e. means. the trachea, lungs and heart were dissected free. The A lung strip was fixed in formal sublimate, stained heart, great vessels and oesophagus were carefully with haematoxylin and eosin and cut into 5 gm sec- removed. The single lobe of the left lung was gently tions. Microscopic examination showed that the prep- teased clear of the surrounding connective tissue and aration consists of alveoli, alveolar ducts, and respira- a ligature tied around the bronchus as it entered the tory bronchioles. parenchyma and the parenchyma removed. This pro- cedure was repeated with the four lobes of the right Drugs lung leaving the trachea and the major and lobar bronchi. The preparation was gently massaged to fill The drugs used were aminophylline (Fisons), atropine it with physiological saline and a PP120 polyethylene sulphate (BDH), histamine acid phosphate (Evans cannula inserted into the trachea up to the bronchial Medical), indomethacin (Merck, Sharpe and Dohme), bifurcation. A ligature was then tied around this can- 5-hydroxytryptamine creatinine phosphate (Ralph nula excluding the trachea from the preparation. Emanuel Limited), isoprenaline hydrochloride (Phar- Changes in intraluminal pressure were recorded with max), methysergide bimaleate (Sandoz), prosta- a Statham P23BB pressure transducer and a Vitatron glandins E1, E2 and F2. (Cambrian Chemicals), flat bed recorder. The preparation was immersed in methacholine chloride (Aldrich Chemicals) and pro- aerated physiological solution at 37°C in an overflow pranolol hydrochloride (ICI). bath and drugs were added to the bathing fluid. Superfused lung strip Results Male Charles River CR/CD rats (250 to 350 g) were Neither the isolated bronchi nor the tracheal tube anaesthetized as above and the trachea, lungs, heart possessed intrinsic tone, but the superfused lung strip and great vessels excised as before. The left lung was started with tone and developed more during the ex- removed and placed in physiological saline. The outer periment. The responses of the trachea and the bron- 2 mm of the lateral margin was cut from the lobe chi were similar throughout and illustrations are to form a strip. Approximately 1.5 cm of this strip shown for the bronchi only. was suspended in an organ bath and aerated physio- logical solution at 37°C was superfused at a flow rate Methacholine of 2ml/min. The tissue was placed under an initial tension of 300mg and changes in tissue tone were Methacholine increased the intraluminal pressure of recorded with a Harvard smooth muscle transducer the bronchi and the trachea. Figure la shows the and a Vitatron recorder. Drugs were added to the effect on the bronchi of methacholine and its inhibi- superfusate via an injection port before the peristaltic tion by atropine sulphate. Figure lb shows the effect pump. of methacholine on the lung strip. Note that atropine THREE RAT AIRWAY PREPARATIONS 73 100l- gonized the effect of 5-HT. Atropine at 10 ng/ml and 100 ng/ml caused a partial antagonism (Figure 2). 0 0) 80 - Isoprenaline c 0 0) Neither the trachea nor the bronchi possessed intrin- 60 F sic tone and isoprenaline had no direct effect on them. E However, isoprenaline caused dose (1 to 10 pg/ml)- E related relaxations of a methacholine-induced con- I 401- traction. These relaxations were small and were anta- E gonized by propranolol (10 ng/ml). The superfused 0~ lung strip possessed intrinsic tone as it was relaxed o-0 2(, by isoprenaline in the dose range of 0.1 to 1 gig/ml. The relaxations were slow in onset and the tissue took about 20 min to regain its tone. Propranolol (10 ng/ml) inhibited the relaxations. lOng lug boug 10Oug 1mg 10mg Aminophylline Dose of 5-HT Figure 2 The effect of 5-hydroxytryptamine Aminophylline relaxed all three tissues in the same (5-HT) on the rat isolated lung strip without atro- manner as isoprenaline. Doses of 10 to 1001g/ml pine sulphate (0); in the presence of atropine sul- were needed to produce partial relaxation of metha- phate 10 ng/ml (-) or 100 ng/mI (A). Each point choline-induced tone on the trachea and bronchi, and represents the mean results from 6 tissues; vertical 500 to 1000 pg were needed to relax the lung strip. lines show s.e. means. Propranolol (10 ng/ml) did not antagonize the relaxa- tions in any of the tissues. causes a dose-related reduction in the maximal re- Prostaglandins sponse to methacholine. Prostaglandins (PG) E1, E2 and F2, had no effect 5-Hydroxytryptamine (5-HT) in concentrations up to 1 gg/ml on four preparations of all three tissues under resting conditions. PGE2 Both the trachea and the bronchi rapidly developed and PGF2<, produced small relaxations of a metha- tachyphylaxis to 5-HT and a 30min slow wash was choline-induced contraction of the trachea and bron- found to be necessary to restore 5-HT's activity. How- chi at 1 gtg/ml. ever, even when using this protracted dose cycle the response to 100 pg was approximately half that of the Histamine initial response to 10 pg on the 5 tissues studied. The maximum response to 5-HT was approximately 25% Histamine had no effect on four preparations of each of that to methacholine. tissue in concentrations as high as 1 mg/ml. The effects of methysergide and atropine were examined on a bronchial preparation. Three consecu- Origin of the tone in superfused lung strip tive doses of 10 pg/ml were given at 30 min intervals. On the third occasion, 10 ng/ml of either atropine or Four lung strips were superfused with physiological methysergide was present. The responses were signifi- solution containing 1 1±g/ml indomethacin.
Recommended publications
  • Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document
    DECEMBER 2015 ALDERLEY PARK THE FUTURE AS A WORLD-CLASS LIFE SCIENCE FACILITY PLANNING APPLICATION SUMMARY DOCUMENT Alderley Park is a world-class Life Science research and development (R&D) facility. The site currently houses around 190,000 sq m of premier scientific laboratory space, offices, restaurants, cafes, conferencing space and energy plant, set in 400 acres of parkland. As a centre for scientific research, it is one of the few facilities in the country with a comprehensive offering to support drug discovery and development. It was AstraZeneca’s global lead centre for cancer research, employing at its peak up to 10,000 people in highly skilled jobs. These facilities at Alderley Park are high-quality A planning application has been submitted to and high-tech, and require significant ongoing Cheshire East Council for future development investment to retain them. £550 million has been at Alderley Park. The planning application invested in Alderley Park since 1997 and further, has been allocated the reference number major investment is required to repurpose the site 15/5401M. from single to multi-occupier use, maintain the facilities and cover ongoing overheads. This summary document sets out the key elements of the proposals. ILLUSTRATIVE MASTERPLAN SIGNIFICANT INVESTMENT PROPOSED OVER THE NEXT 10 YEARS In March 2013, AstraZeneca announced The site was purchased by Bruntwood/MSP, its decision to relocate its R&D facilities to part of Alderley Park Ltd who now wish to Cambridge, leading to uncertainty over the secure the future of the site, retaining talent and future of Alderley Park and its role in the local jobs, by taking forward the Taskforce’s vision.
    [Show full text]
  • Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting
    Author Manuscript Published OnlineFirst on December 16, 2013; DOI: 10.1158/1535-7163.MCT-13-0420 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fully Human Anti-Hedgehog Antibodies Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Authors: Neil R. Michaud1*, Youzhen Wang1, Kristen McEachern1, Jerold J. Jordan1, Anne Marie Mazzola1, Axel Hernandez1, Sanjoo Jalla2, Jon W. Chesebrough2, Mark J. Hynes3, Matthew Belmonte 1, Lidong Wang3, Jaspal S. Kang4#, Jelena Jovanović5, Naomi Laing1, David W. Jenkins1, Elaine Hurt2, Meina Liang6, Christopher Frantz7, Robert E. Hollingsworth2, Diane M. Simeone3, David C. Blakey8, and Vahe Bedian1* Authors’ affiliation: 1Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 2Oncology Research, MedImmune LLC, Gaithersburg, MD 3Translational Oncology Program, University of Michigan, Ann Arbor, MI; 4Amgen British Columbia, Burnaby, BC, Canada 5Lead Generation- Research, Medimmune LLC, Granta Park, Cambridge, UK 6Clinical Pharmacology and DMPK, MedImmune LLC, Hayward, CA 7Biologics Safety Assessment, MedImmune LLC, Mountain View, CA 8Oncology iMed, AstraZeneca, Alderley Park, Macclesfield. UK #Current address: Paul Kang, CSO, Innovative Targeting Solutions Inc., Burnaby BC, Canada *corresponding authors: Neil R. Michaud, Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 e-mail: [email protected] Vahe Bedian Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 phone:781-839-4613 e-mail: [email protected] Running title: Fully Human Anti-Hedgehog Antibodies Key Words: Hedgehog, Antibody, Xenograft, XenoMouse, cancer stem cells Grant Support: This work was funded by AstraZeneca PLC and MedImmune LLC. Disclosure of Potential Conflicts of Interest: There are no potential conflicts of interest.
    [Show full text]
  • 6Th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25Th - 26Th Sept 2014
    6th Annual Translational Medicine Conference ‘Personalising Health and Care’ Date: 25th and 26th September 2014 | Venue: City Hotel, Derry/Londonderry, N.Ireland, UK 1 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Conference Sponsors 2 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Contents Page Conference Programme .................................................................................... 4 Biographies .......................................................................................................... 6 - 9 Delegate List ........................................................................................................ 10 - 12 Bio-Entrepreneur Programme........................................................................ 13 About C-TRIC ....................................................................................................... 14 - 15 Abstracts Poster Presentations................................................................. 16 - 42 Abstracts Oral Presentations................................................................. 43 Abstracts Poster List................................................................. 44 3 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 ‘Personalising Health and Care’ - Conference Programme Day One Thursday 25th Sept 1:00 pm Registration and Tea/Coffee 4.30 pm Oral
    [Show full text]
  • Alderley Park Development Framework
    Alderley Park Development Framework Consultation Draft - January 2015 0i 2 Contents 1 Introduction 2 The Site 3 Planning Policy 4 Design Guidance 5 Indicative Masterplan 6 Planning Applications 7 Summary and Next Steps Appendices 3 1 Introduction Alderley Park, a research and development site The Taskforce commissioned a study to establish the new vision for the site. It allocates Alderley Park as an renowned for the discovery and development of potential future demand from the life science sector, for ‘opportunity site’, seeking to promote and encourage the innovative new medicines, is a key part of the North the world class laboratory and office space on site1. That development of the Life Science Park whilst recognising West Life Science Ecosystem. Opening more than 40 study indicated that whilst there would not by any means that there is likely to be a need for a degree of flexibility years ago, the site has a rich heritage of important be an instant demand for all the site’s facilities, with an regarding land uses to deliver, grow and sustain the Life advancements in medical treatments, including a appropriate business model, there is potential to build on Science Park vision. number of anti-cancer treatments. As the lead centre the BioHub concept, repurposing the site to offer facilities Until the adoption of the CELPS, the current development for cancer research, Alderley Park currently houses which complement existing life science resources across plan for the area remains the Macclesfield Borough the global Advanced Lead Discovery Centre, and its the region, such that Alderley Park can continue to be a Local Plan.
    [Show full text]
  • Directions to Alderley Park Conference Centre
    Directions to Alderley Park Conference Centre Travel by rail Travel by road Travel by air A regular shuttle service from Alderley Alderley Park is centrally located on Alderley Park is located within 20 minutes Park provides convenient transfer from both the UK’s North/South and East/ drive time on uncongested roads to nearby Wilmslow and Macclesfield mainline West motorway network. The main M6 Manchester Airport, which serves more stations, connecting with direct services motorway is just 20 minutes’ drive away destinations than any other airport in to London that run every 20 minutes and on uncongested roads. Manchester city the UK. This top 20 international airport take under two hours. Manchester is a key centre can be accessed in 40 minutes and handles over 22m passengers every year rail hub on the West Coast mainline linking Liverpool and Leeds can be reached within to over 220 worldwide destinations allowing London with Scotland as well as being the one hours’ drive time, with Birmingham comprehensive direct flight access to main arterial rail link between England, two hours drive time from site. On-site car Europe, the US and the Far East. In addition Wales and Scotland. parks at Alderley Park can accommodate Liverpool airport is 40 miles away and approximately 4,000 vehicles. Birmingham West Midlands is 71 miles away. Regional map Local map TO MANCHESTER AIRPORT M6 to Preston, M62 to Leeds MANCHESTER Carlisle, Scotland ROAD 4 3 A34 - TO M66 A M6 Rochdale M60 J3 & MANCHESTER Heywood Bury M62 W A T E R L A Bolton N E 8 WILMSLOW
    [Show full text]
  • Large-Scale Isolation of Human Skeletal Muscle Satellite Cells from Post-Mortem Tissue and Development of Quantitative Assays to Evaluate Modulators of Myogenesis
    J Cachexia Sarcopenia Muscle (2013) 4:157–169 DOI 10.1007/s13539-012-0097-z ORIGINAL ARTICLE Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis Ian C. Scott & Wendy Tomlinson & Andrew Walding & Beverley Isherwood & Iain G. Dougall Received: 24 July 2012 /Accepted: 25 November 2012 /Published online: 24 January 2013 # Springer-Verlag Berlin Heidelberg 2013 Abstract Methods Satellite cells were isolated by digestion of post- Background During aging, there is a decreased ability to mortem skeletal muscle and selection using anti-CD56 maintain skeletal muscle mass and function (sarcopenia). MicroBeads. CD56+ cell-derived myotubes were quantified Such changes in skeletal muscle are also co-morbidities by high content imaging of myosin heavy chains. TaqMan- of diseases including cancer, congestive heart failure polymerase chain reaction arrays were used to quantify expres- and chronic obstructive pulmonary disease. The loss of sion of 41 selected genes during differentiation. The muscle mass results in decreased strength and exercise effects of activin receptor agonists and tumour necrosis tolerance and reduced ability to perform daily activities. factor alpha (TNFα) on myogenesis and gene expres- Pharmacological agents addressing these pathologies sion were characterised. could have significant clinical impact, but their identifi- Results Large-scale isolation of CD56+ cells enabled devel- cation requires understanding of mechanisms driving opment of a quantitative myogenesis assay with maximal myotube formation (myogenesis) and atrophy and pro- myotube formation 3 days after initiating differentiation. vision of relevant assays. The aim of this study was to Gene expression analysis demonstrated expression of 19 develop robust in vitro methods to study human genes changed substantially during myogenesis.
    [Show full text]
  • Cardiovascular Safety Risk Assessment for New Candidate Drugs from Functional and Pathological Data
    Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data 14th & 15th November 2013 Alderley Park Conference Centre, Cheshire, UK The 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data th th 14 & 15 November 2013, Alderley Park Conference Centre, UK 28th ANNUAL SCIENTIFIC MEETING of the BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY held jointly with the SAFETY PHARMACOLOGY SOCIETY I am delighted to welcome you to the 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) and sponsored by the Health and Environmental Sciences Institute (HESI) at The Alderley Park Conference Centre, Cheshire, UK on 14th and 15th November 2013. The excellent programme on offer at this meeting is a tribute to the work of many people, including the BSTP Council and Education Sub-Committee. However, I would particularly like to thank the Scientific Organisers, Stephanie Klein and Will Redfern, for their ideas and energy in successfully combining morphologic and functional aspects of cardiovascular toxicology. This was the aspiration of the meeting and I think it has been fulfilled. We know that much scientific progress is made at the intersection of different disciplines, and the BSTP is keen to establish fruitful collaborations with many other societies. This results in meetings of wider interest and allows for hot topics at the edge of our current understanding to be discussed. This meeting, organised with Jean-Pierre Valentin of the SPS, very much exemplifies this approach and I hope it forms the template of many more to come.
    [Show full text]
  • Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected]
    The Royal Society of Biology Register of Eligible Qualified Persons – Web Version Copyright © 2013 The Royal Society of Biology All rights reserved No part of this register may be reproduced, copied or transmitted in any form or by any means without written permission from the Royal Society of Biology Anyone wishing to use details from the Register must contact the Professional Registers Programme Manager BAKER, C CBiol MRSB QualiPharm Consultancy Ltd Tel: 07968 266691 Email: [email protected] Website: www.qualipharm.co.uk Registered 2007 BARNARD DD, CBiol Holly Lodge LLantilio Crossenny Monmouthshire NP7 8TF Registered 1992 BERLANGA H, CBiol MRSB Allergy Therapeutics plc Dominion Way | Worthing West Sussex BN14 8SA Tel: 01903 844 703 Email: [email protected] Website: www.allergytherapeutics.com Registered 2011 BIRCH I, CBiol MRSB BECO Integrated Services Ltd Email: [email protected] Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected] www.rsb.org.uk Registered Charity No.277981 Incorporated by Royal Charter Registered 2010 BURROWS M, MRSB Shire Pharmaceuticals Ireland Ltd Miesian Plaza 50 -58 Lower Baggot Street Dublin DO2 Y754 Tel: 0877112159 Email: [email protected] Registered 2015 CALLAGHAN M, MRSB Piramal Pharma Solutions Email: [email protected] CHESTERTON NJ, MRSB Dolby Vivisol Unit 18 Arkwright Road Bedford Bedfordshire MK42 0LQ Tel: 07584 086330 Email: [email protected] Registered 2011 CLACK S, CBiol MRSB Quaph Consulting
    [Show full text]
  • Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report
    Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report Commercial in Confidence 29 January 2014 Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 4 3. Research Method & Impact Parameters .......................................................................... 13 4. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘pre-disinvestment ’ ................................................................................................................................................. 22 5. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘post-disinvestment ’ ................................................................................................................................................. 33 6. The Wider Qualitative effects of disinvestment .............................................................. 37 7. Perspectives on the Spatial Effects and Consequences of Disinvestment ................. 43 8. Conclusions & Recommendations ..................................................................................
    [Show full text]
  • The Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Final Report Contents
    The i mpact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 2: Future Market Demand Assessment Final Report Commercial in Confidence 11 February 2014 The impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Final Report Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 5 3. Thinking & Planning for Demand ..................................................................................... 30 4. Projection 1 – An Initial Perspective on Demand ........................................................... 43 5. Qualitative Perspectives on Demand – the General View ............................................. 53 6. Qualitative Perspectives on Demand – the particular case of HE and Research Institutes ................................................................................................................................. 72 7. Projection 2 - A Revised Perspective on Demand .......................................................... 78 8. The Story of Existing and Pipeline Supply ...................................................................... 81 9. A Forward View of Economic Impact ..............................................................................
    [Show full text]
  • 022405Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022405Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Vandetanib Date: March 25, 2011 To: File for NDA 22405 From: John K. Leighton, PhD, DABT Associate Director for Pharmacology/Toxicology Office of Oncology Drug Products I have examined pharmacology/toxicology supporting review and labeling provided by Drs. Gehrke and Dorsam and supervisory memorandum provided by Dr. Verbois. I concur with their conclusions that vandetanib may be approved for the proposed indication with the carcinogenicity studies to be provided as described in the Action Letter. Reference ID: 2923639 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 03/25/2011 Reference ID: 2923639 MEMORANDUM Date: March 25, 2011 From: S. Leigh Verbois, Ph.D. Supervisory Pharmacologist Division of Drug Oncology Products To: File for NDA #022405 Vandetinib Re: Approvability of Pharmacology and Toxicology Non-clinical studies that investigated the pharmacology and toxicology of vandetinib provided to support NDA 022405 for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer were reviewed in detail by Brenda Gehrke,
    [Show full text]
  • Site Selection Final Report: Alderley Park
    Cheshire East Local Plan Site Selection Final Report: Alderley Park July 2016 Contents 1 Introduction 1 2 Sustainability Appraisal 2 3 Neighbourhood Plan 2 4 Sites Assessed and Recommendation 2 Site PSS1200 2 5 Overall Conclusion (Stage 9) 6 Appendices Appendix 1: Site Map 7 Appendix 2: Traffic Light Form 9 Appendix 3: Vision and Strategic Priorities Form 16 Appendix 4: Summary of Infrastructure Providers and Statutory Consultee Comments 20 Cheshire East Local Plan Strategy: Final Site Selection Report Alderley Park 1. Introduction 1.1 The ‘Cheshire East Local Plan Strategy: Site Selection Report – Alderley Park was published as background evidence to the Cheshire East Local Plan Strategy Proposed Changes Version (LPS) consultation, which took place from 4 March to 19 April 2016. The Report documented the implementation of the Site Selection Methodology (SSM) for Alderley Park. 1.2 This Report considers: (i) any additional information that has been submitted, in relation to the site and whether such information means that the conclusion and recommendation, using the SSM should change, in relation to the site; (ii) the responses, relating to the site, submitted to the public consultation in March/April 2016. 1.3 This Report supersedes the March 2016 Report; it makes it clear where circumstances have changed in relation to the site and makes recommendations accordingly, some of which may be different to those made in the March 2016 Report. 1.4 This Report should be read alongside the SSM report (and its associated evidential documents, including the Urban Potential Assessment (UPA) [PS E039b], and Edge of Settlement Assessment (ESA) [PS E039b]), the Sustainability Appraisal (SA)/Habitats Regulations Assessment (HRA), and the Cheshire East Council Proposed Changes to the Local Plan Strategy (Consultation Draft) February 2016.
    [Show full text]